Established in 1997, Prana Biotechnology is a world leader in addressing the role of biological metals in human disease. Abundant scientific evidence suggests that many age-related conditions result from pathological interactions between selected metals and target proteins. The company has developed a proprietary library of chemical compounds that target these interactions, preventing protein aggregation and corruption. The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration.

Latest News  2 February 2012 Prana Comments on Articles that Highlight the Role of Metals in Neurodegenerative Diseases       Learn more 11 January 2012 Professor Tanzi Appointed Prana's Chief Scientific Officer      Jearn more 4 January 2012 FDA Approval to Commence Huntington's Diease Clinical Trial Using Prana's PBT2      Learn more 16 December 2011 Landmark Publication Endorses Prana's Strategy      Learn more  15 December 2011 Prana Commences Alzheimer's Trial Recruitment.      Learn more 28 November 2011 Prana secures key patent for Parkinson's drug PBT434 in the United States       Learn more  22 November 2011 Prana Receives Approval for Alzheimer's Trial       Learn more 14 November 2011 PBT2 reverses the loss of synaptic activity in neurons       Learn more 27 October 2011 Australian Federal Government grant to study role of PBT2 in preventing excitotoxicity         Learn more 20 October 2011 Government Grant to Study Effect of PBT2 in the Ageing Brain         Learn more 19 September 2011 PBT2 Directly Restores Neurons Critical to Cognition - important further demonstration of mechanism of action         Learn more     PBT2 Therapeutic Strategy Statement Subscribe / E-mail alerts